Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Core Viewpoint - Unicycive Therapeutics, Inc. is actively participating in the biotech sector, focusing on developing therapies for kidney diseases, with significant upcoming events and investigational treatments under review [1][3]. Group 1: Company Overview - Unicycive Therapeutics is a clinical-stage biotechnology company dedicated to developing novel treatments for kidney diseases [3]. - The company's lead investigational treatment, oxylanthanum carbonate, is currently under review by the U.S. Food and Drug Administration (FDA) for treating hyperphosphatemia in patients with chronic kidney disease on dialysis [3]. - Unicycive's second investigational treatment, UNI-494, targets conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [3]. Group 2: Upcoming Events - Shalabh Gupta, M.D., the CEO of Unicycive, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 1:30 p.m. ET [1]. - A live and archived webcast of the event will be available on the Unicycive website under the Investors section [2].